More than a dozen medical device, pharmaceutical and diagnostics companies made it to the top 100 of this year’s Deloitte’s Fast 500 Ranking.
Each year, Deloitte compiles the list that highlights 500 of the fastest-growing tech companies in the U.S., as determined by revenue growth as submitted by the company. That means that most of the medical companies on the list were later-stage companies with products on the market.
Here are a few teasers from the top 100:
Inside an Automated Healthcare Practice: Redesigning Care Around People, Not Paperwork
By reducing administrative burden and redesigning workflows around human needs, it creates space for what matters most: connection between clinicians and patients.
HeartWare Inc. (NASDAQ:HTWR) – Received FDA clearance last year for a left ventricle assist device for heart failure patients awaiting heart transplant.
AxoGen Inc. (NASDAQ:AXGN) – Wants to equip surgeons with better tools to repair and protect peripheral nerves.
Boston Heart Diagnostics – Offers a portfolio of tests designed to identify cardiovascular risk and select the best treatment for each patient.
Merrimack Pharmaceuticals Inc. (NASDAQ:MACK) – Developing drugs and companion diagnostics for the treatment of cancer. Currently has six oncology drugs in clinical development.
The Hidden Administrative Tasks Draining Small Practices
Small practices play a critical role in healthcare delivery, but they cannot continue to absorb ever-increasing administrative demands without consequences.
Endocyte (NASDAQ:ECYU) – Has multiple small molecule cancer drugs in clinical trials and is developing companion imaging diagnostics to go along with them.
Novavax (NASDAQ:NVAX) – Using nanotechnology to develop vaccines and vaccine adjuvants for infectious diseases.
See the full list here (PDF).